Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Because health is shaped by a variety of interconnected factors–clinical, biological, genetic, environmental and social–the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program seeks to integrate clinical imaging with relevant, complementary multimodal data (MMD). The overarching goal of the PRIMED-AI Program is to catalyze the development and adoption of innovative AI-based CDS tools into clinical workflows. The PRIMED-AI Program initiatives collectively aim to tackle complex clinical challenges by fostering cross-disciplinary collaboration to create innovative, reliable, cost-effective, and sustainable AI solutions that enable precision medicine strategies.
RFA-RM-27-013: To catalyze the translation of Artificial Intelligence (AI)-enabled, image-centered, multimodal clinical decision support (CDS) tools, developed as Software as a Medical Device (SaMD), from training and testing of prototypes towards clinical applications that address unmet health challenges in precision medicine.
UG3 Phase (Exploratory/Developmental): This initial phase focuses on establishing the technical and operational foundation for clinical translation. Projects will develop and refine AI models, regulatory preparations, clinical implementation infrastructure, deployment strategies, and demonstrate preliminary feasibility in target clinical settings. Milestones must be achieved before transitioning to the UH3 phase.
UH3 Phase (Advanced Development): Following successful completion of the UG3 phase, the UH3 phase emphasizes CDS model clinical implementation and validation. Projects will deploy CDS tools in clinical workflows; conduct prospective clinical studies to evaluate performance; demonstrate potential for impact and integration with existing health IT systems; and generate evidence for broader adoption and sustainability. Projects must demonstrate measurable potential for clinical impact and pathway(s) to sustained use beyond the award period.
Application deadline: October 19, 2026